Glenmark Pharmaceuticals Limited (GLENMARK) announced today that it has received U.S. FDA approval to expand the use of RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. This approval extends the use of RYALTRIS® to a younger pediatric population, marking a significant milestone in Glenmark’s innovative respiratory portfolio.

Impact on Pediatric Patients

The approval was supported by a Phase 3, randomized, double-blind, placebo-controlled study involving 446 children aged 6 to 11 years with Seasonal Allergic Rhinitis. The study demonstrated that RYALTRIS® improved nasal symptoms compared with placebo and was well tolerated over the 14-day treatment period. This development is particularly important as seasonal allergies are common among school-age children in the United States, affecting their overall health, emotional well-being, sleep, and participation in physical activity.

Strategic Growth for Glenmark

Marc Kikuchi, President & Business Head, North America, commented, “This approval marks an important step in expanding access to RYALTRIS® in the United States by extending its use to children aged 6 to less than 12 years with Seasonal Allergic Rhinitis. It also strengthens the role of RYALTRIS® as a key innovative brand within Glenmark’s growing US respiratory portfolio.” The transition to direct commercialization has given Glenmark greater ownership of the brand, enabling closer engagement with healthcare professionals and patients.

Effective April 1, 2026, Glenmark Pharmaceuticals Inc., USA assumed responsibility for the end-to-end commercialization and distribution of RYALTRIS® in the United States. Glenmark now directly leads the product’s brand strategy, market access, distribution, and customer engagement, enabling more focused execution and closer alignment with the needs of healthcare professionals and patients.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Glenmark holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.70 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 8.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock holds at 66% of its 52-week range with RSI at 50. In other words, neither side has a clear edge right now. Revenue grows at 13.5% and profits at 66.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Glenmark Pharmaceuticals Limited.

Glenmark Pharmaceuticals Limited (GLENMARK) is pleased to announce the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the USA. Glenmark’s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa® IntraMuscular Injection 10 mg/vial of Cheplapharm Registration GmbH [NDA 021253]. According to IQVIA® sales data for the 12-month period ending May 2026, the Zyprexa® IntraMuscular Injection market achieved annual sales of approximately $25.4 million.

Strategic Focus on Injectables

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers.”

Market Potential

The launch highlights Glenmark’s dedication to innovation and accessibility in the pharmaceutical sector. Olanzapine for Injection is only approved for the indications listed in Glenmark’s approved label, which may differ from the approved reference listed drug indications. This strategic move is expected to bolster Glenmark’s market presence and contribute to its mission of delivering high-quality, affordable medicines globally.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Glenmark holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.69 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 8.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Sellers drive 1.5x the volume of buyers. Furthermore, they controlled 13 of recent sessions versus 16 for buyers — a clear distribution signal. Revenue grows at 13.5% and profits at 66.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Glenmark Pharmaceuticals Limited.

Glenmark Pharmaceuticals Limited (GLENMARK) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC). India will serve as the first country in Glenmark’s licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). Glenmark also plans to enroll patients in Australia and South Korea, subject to regulatory approvals. The study is aligned with Jiangsu Hengrui Pharmaceuticals Co. Ltd.’s ongoing parent Phase 3 trial in China.

Clinical Trial Details

The randomized, controlled, multi-centre, Phase 3 trial is designed to evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab rezetecan in patients with HER2-expressing platinum-resistant ovarian cancer. Conducting the trial across multiple geographies is expected to support the generation of evidence from diverse patient groups and strengthen the clinical data package for the therapy across Glenmark’s licensed markets.

Significance of the Trial

Commenting on the announcement, Dr. Monika Tandon, Global Head of Clinical Development, Glenmark Pharmaceuticals Limited, said, “Advancing this pivotal Phase 3 trial marks an important step in Glenmark’s journey to build a differentiated oncology pipeline for global markets. Platinum-resistant ovarian cancer remains an area of significant unmet need, and the initiation of patient enrollment in India, with additional countries planned, reflects our commitment to developing novel targeted therapies for patients with hard-to-treat cancers and limited treatment options. This study also strengthens our ability to generate clinically relevant evidence across diverse populations.”

Ovarian cancer remains one of the most challenging gynecologic malignancies globally. It is the eighth most common cancer among women worldwide. India carries a significant burden, ranking among the countries with the highest number of ovarian cancer cases and deaths globally. Many patients with advanced ovarian cancer treated with available platinum-based therapies develop recurrence and subsequently platinum resistance. This underscores the need for continued clinical development of targeted therapies that may improve treatment options for patients with advanced and resistant disease.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Glenmark posts a 3.4% three-month gain, but softens in the last few weeks. The PEG of 0.68 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 8.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Sellers drive 1.6x the volume of buyers. Furthermore, they controlled 14 of recent sessions versus 15 for buyers — a clear distribution signal. Revenue grows at 13.5% and profits at 66.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Glenmark Pharmaceuticals Limited.